Durata submits dalbavancin MAA

Durata Therapeutics Inc. (NASDAQ:DRTX) submitted an MAA to EMA for dalbavancin ( RQ-00000002) to treat complicated skin and soft tissue infections (cSSTI) caused by susceptible Gram-positive microogra...